Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.42 |
| ▸ | MYLK4 | Q86YV6 | 3/20 | 0.42 |
| ▸ | ECE1 | P42892 | 2/20 | 0.41 |
| ▸ | MME | P08473 | 4/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10826450 | 0.88 | MME (0.46) | MMEACE2 | |
| SCHEMBL31734674 | 0.86 | MME (0.41) | MMEACE2 | |
| SCHEMBL8957080 | 0.85 | CTSB (0.43) | MMEACE2 | |
| SCHEMBL8957088 | 0.85 | CTSB (0.43) | MMEACE2 | |
| SCHEMBL31735189 | 0.82 | CYP3A4 (0.35) | — | |
| SCHEMBL10826528 | 0.81 | MME (0.52) | MME | |
| SCHEMBL9666897 | 0.80 | CTSC (0.47) | MME | |
| SCHEMBL7277013 | 0.80 | CTSC (0.47) | MME | |
| SCHEMBL9667566 | 0.80 | CTSC (0.47) | MME | |
| SCHEMBL3881794 | 0.80 | CTSC (0.47) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041157-B1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | FLAMMA SPA (IT) | 2015-05-06 | — | — | EP | claimed |
| US-8765798-B2 | Peptide derivatives with therapeutic activity | FLAMMA S.P.A. (IT) | 2014-07-01 | — | — | US | claimed |
| US-20090247601-A1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | FLAMMA S.P.A. (IT) | 2009-10-01 | — | — | US | claimed |
| EP-2041157-A1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | Flamma S.P.A. (IT) | 2009-04-01 | — | — | EP | claimed |
| WO-2008001174-A1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | FLAMMA, S.P.A. (IT) | 2008-01-03 | — | — | WO | claimed |
| EP-2041157-B1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | FLAMMA SPA (IT) | 2015-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247601-A1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | IAPP, VIP, DNPEP | ROCK1 3064/4885MYLK4 3158/4885ECE1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.